|
|
Volumn 27, Issue 1, 2008, Pages
|
|
Interview - Insurers and 'targeted biologics' for cancer: A conversation with Lee N. Newcomer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
RITUXIMAB;
TRASTUZUMAB;
VASCULOTROPIN;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER THERAPY;
CLINICAL TRIAL;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
DATA COLLECTION METHOD;
DECISION MAKING;
DIAGNOSTIC TEST;
DRUG COST;
DRUG EFFICACY;
DRUG TARGETING;
ECONOMIC ASPECT;
FOLLOW UP;
GENETIC PROCEDURES;
GOVERNMENT;
HEALTH CARE;
HEALTH INSURANCE;
HUMAN;
LUNG CANCER;
LYMPHOMA;
MEDICAL PRACTICE;
MORTALITY;
NOTE;
OFF LABEL DRUG USE;
ONCOLOGY;
PANCREAS CANCER;
PHYSICIAN;
QUALITY CONTROL;
RETROSPECTIVE STUDY;
RISK FACTOR;
ARTICLE;
DRUG DELIVERY SYSTEM;
ECONOMICS;
HEALTH CARE POLICY;
INTERVIEW;
NEOPLASM;
UNITED STATES;
DRUG DELIVERY SYSTEMS;
HEALTH POLICY;
HUMANS;
INSURANCE, HEALTH;
MEDICAL ONCOLOGY;
NEOPLASMS;
UNITED STATES;
|
|
EID: 40949091996
PISSN: 02782715
EISSN: 02782715
Source Type: Journal
DOI: 10.1377/hlthaff.27.1.w41 Document Type: Note |
|
Times cited : (13)
|
|
References (0)
|
